1. Scrip
  2. >>Business
  3. >>Financing

IPOs Fizzle Out In The Fourth Quarter

 
• By Elizabeth Cairns

Just three biotech companies floated in the last three months of 2023, but there may be hope for a resurgence next year.  

Nasdaq ipo

The tail end of the year is often a weak period for biotech flotations, so perhaps the fact that the companies that went public in Q4 of 2023 managed to raise more than those in either Q1 or Q2 is a hopeful sign.

Key Takeaways
  • Just three floating biotechs raised a total of $617m in the fourth quarter of last year

Still, the $617m raised over the past three months is a retrenchment from the $1.3bn seen in Q3 of 2023....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By Mandy Jackson

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.